Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Canertinib as an FLT3 Inhibitor with Potent Activity Against FLT3-Mutated and AC220-Resistant Acute Myeloid Leukemia.

Journal of visualized experiments : JoVE - 5 Dec 2025

Pang Hongfeng, Wan Chaoling, Zhang Maofeng, Ge Shuaishuai, Huang Yuanhong, Qiu Chengqiao, Xue Shengli, Wu Depei, Liu Songbai

Abstract excerpt

FMS-like tyrosine kinase 3 (FLT3) mutations are among the most common genetic lesions in acute myeloid leukemia (AML) and are frequently associated with high relapse rates and poor prognosis. Although current FLT3 inhibitors have improved outcomes, acquired resistance limits their long-term efficacy. Accordingly, developing new FLT3 inhibitors is important. We screened a natural-compound library to identify small...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carbazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Morpholines

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 41428627
DOI: 10.3791/69655

Genes

FLT3
ACR
CCK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Canertinib as an FLT3 Inhibitor with Potent Activity Against FLT3-Mutated and AC220-Resistant Acute Myeloid Leukemia.PMID 41428627Read ↗

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.Semantic proximity Read ↗

Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells.Semantic proximity Read ↗

Nintedanib is a potent FLT3 inhibitor with activity against FLT3-ITD and overcomes the gatekeeper F691L resistance mutation in acute myeloid leukemia.Semantic proximity Read ↗

Investigational drugs targeting FLT3 for leukemia.Semantic proximity Read ↗

The clinical development of FLT3 inhibitors in acute myeloid leukemiaSemantic proximity Read ↗

Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AMLSemantic proximity Read ↗

Discovery of a Potent and Selective FLT3 Inhibitor (Z)-N-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia.Semantic proximity Read ↗

FLT3 tyrosine kinase inhibitors.Semantic proximity Read ↗

CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells.Semantic proximity Read ↗

Discovery of Oxazol-2-amine Derivatives as Potent Novel FLT3 Inhibitors.Semantic proximity Read ↗

FLT3 inhibitors: a story of the old and the new.Semantic proximity Read ↗

FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.